{"id":7484,"date":"2025-08-08T11:10:18","date_gmt":"2025-08-08T09:10:18","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=clinical-trial&p=7484"},"modified":"2025-08-08T11:10:18","modified_gmt":"2025-08-08T09:10:18","slug":"cadance-101-trial","status":"publish","type":"clinical-trial","link":"https:\/\/beonemedaffairs.com\/us\/clinical-trial\/7484\/cadance-101-trial\/","title":{"rendered":"CaDAnCe-101 Trial"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-7484","clinical-trial","type-clinical-trial","status-publish","hentry","content_type-reading","disease_state-b-cell-malignancies","disease_state-chronic-lymphocytic-leukemia","disease_state-diffuse-large-b-cell-lymphoma","disease_state-follicular-lymphoma","disease_state-marginal-zone-lymphoma","disease_state-small-lymphocytic-lymphoma","disease_state-waldenstroms-macroglobulinemia","molecule-bgb-16673"],"acf":{"summary":"CaDAnCe-101 (NCT05006716) is a Phase 1\/2, open-label, dose-escalation and expansion trial evaluating BGB-16673, a Bruton tyrosine kinase (BTK) degrader, in patients with relapsed\/refractory B-cell malignancies, including chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL), follicular lymphoma (FL), and marginal zone lymphoma (MZL).","study_status":"recruiting","cancer_type":false,"authors":"","related_posts":[{"id":7461,"title":"CaDAnCe-101 Trial","title_guest":"","summary":"CaDAnCe-101 (NCT05006716) is a Phase 1\/2, open-label, dose-escalation and expansion trial evaluating BGB-16673, a Bruton tyrosine kinase (BTK) degrader, in patients with relapsed\/refractory B-cell malignancies, including chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL), follicular lymphoma (FL), and marginal zone lymphoma (MZL).","summary_guest":"","content-type":4,"post_image":7462,"blur_thumbnail_guest":false,"post_image_guest":false,"videolange":null,"url":"https:\/\/beonemedaffairs.com\/us\/7461\/cadance-101-trial\/","date":"2025-08-08T10:31:47","date_gmt":"2025-08-08T08:31:47"}],"content-type":246,"download_file_reading":null,"display_file_reading":null,"download_file_slidekit":null,"display_file_slidekit":null,"3qsdn":"","webcast":"","videolange":null,"fliphtml_link":""},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/clinical-trial\/7484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/clinical-trial"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/clinical-trial"}],"acf:term":[{"embeddable":true,"taxonomy":"content_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/content_type\/246"}],"acf:post":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/posts\/7461"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7484"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}